Quick Answer
VERTEX PHARMACEUTICALS INC / MA reported Operating Income of $4.17 billion for fiscal year 2025.
VERTEX PHARMACEUTICALS INC / MA Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | $4.17B | +1891.9% |
| 2024 | -$232.90M | -106.1% |
| 2023 | $3.83B | -11.0% |
| 2022 | $4.31B | +54.8% |
| 2021 | $2.78B | -2.6% |
| 2020 | $2.86B | +138.5% |
| 2019 | $1.20B | +88.5% |
| 2018 | $635.15M | +415.4% |
| 2017 | $123.24M | +1140.4% |
| 2016 | $9.94M | +102.1% |
| 2015 | -$466.88M | +32.6% |
| 2014 | -$692.41M | -13.5% |
| 2013 | -$610.01M | -1405.5% |
| 2012 | $46.73M | -58.9% |
| 2011 | $113.82M | +116.4% |
| 2010 | -$696.08M | -13.4% |
| 2009 | -$614.01M | -32.7% |
| 2008 | -$462.71M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.19B | +6.3% | +3.0% |
| June 30, 2025 | $1.15B | +132.8% | +82.7% |
| March 31, 2025 | $630.10M | -44.7% | -43.6% |
| September 30, 2024 | $1.12B | +7.5% | +131.8% |
| June 30, 2024 | -$3.51B | -442.4% | -408.4% |
| March 31, 2024 | $1.14B | +46.3% | +9.8% |
| September 30, 2023 | $1.04B | -7.9% | +1.1% |
| June 30, 2023 | $1.03B | -7.2% | +31.8% |
- VERTEX PHARMACEUTICALS INC / MA showed an increase of +1891.9% in Operating Income compared to the prior fiscal year.
- Over the 2008–2025 period, VERTEX PHARMACEUTICALS INC / MA’s operating income has grown by 1001.9% (from -$462.71 million to $4.17 billion).
- The most recent figure is from VERTEX PHARMACEUTICALS INC / MA’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: